Phase 2 study for people with Chronic Rhinosinusitis

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor Oticara Australia PTY LTD
Registry number NCT05882903
Started 17 August 2023 Today 16 October 2026 Estimated completion 1 June 2025

Past estimated completion. The registry still lists this trial as open, and the date it gave for finishing has been and gone. Confirm with the official record before you act on it.

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Oticara Investigational Site Sydney NSW Recruiting
Oticara Investigational Site Brisbane QLD Recruiting
Oticara Investigational Site Adelaide SA Recruiting
Oticara Investigational Site Perth WA Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years to 80 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 24

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Adult patients with a clinically confirmed diagnosis of CRS by an otolaryngologist (ENT) undergoing maximal medical therapy as part of their standard of care.

* Having undergone functional endoscopic sinus surgery (FESS) at least 6 months prior to enrolment.

* For each nostril, an endoscopic nasal polyp score of 0, 1, or 2 out of a maximum score of - (where 0= No polyps, 1= small polyps in the middle meatus not reaching below the inferior border of the middle turbinate , 2= nasal polyps reaching below the border of the middle turbinate, 3= large nasal polyps reaching the lower border of the inferior turbinate or nasal polyps medial to the middle turbinate, 4= large nasal polyps causing almost complete obstruction of the inferior nasal cavity) (Gevaert et al, 2023).

* Visible middle turbinates and access to the ethmoid sinuses for dosing as established via endoscopic examination.

* Participants must have a \> 2 on the disease severity visual analogue scale (VAS) at screening and pre-treatment.

* Body weight: A minimum body weight \>=40 kilograms (kg) and a BMI of ≤ 39 at the screening visit.

* Individuals of childbearing potential must use adequate birth control methods and not plan to get pregnant during the study.

* Informed consent: Willingness to give written informed consent and willingness to participate in and comply with the study.

* Age ≥18 but \<80 years.

Exclusion Criteria:

* Subjects with known hypersensitivity or contraindications to betamethasone dipropionate, mometasone, or topical anaesthesia.

* Subjects with sino-nasal abnormalities, disease, or implanted devices that prevents the application of the therapy.

* Previous enrolment in this study.

* Subjects currently receiving systemic corticosteroid or have received systemic corticosteroid in the prior 4 weeks or receiving biologic therapy.

* Subjects with a history of glaucoma or cataracts or have an abnormal intraocular pressure (IOP) at screening or pre-treatment (abnormal IOP is defined as greater than 21 mm Hg).

* Subjects with acute sinusitis.

* Subjects with known immunodeficiency.

* Subjects with diabetes (Type 1).

* Subjects with cystic fibrosis.

* Pregnant subjects or subjects trying to get pregnant or currently lactating as the effect on human pregnancy is unknown.

* Subjects who are unable to give an informed consent because of mental illness, dementia or communication difficulties.

* Subjects with a Cushing's disease diagnosis within the previous 12 months.

* Severe septal deviation and or previous total resection of the middle turbinate.

* Any lab abnormality or underlying medical condition which, in the Investigator's opinion, should exclude the participant.

* Subjects who are unlikely to comply with study procedures, restrictions and requirements as determined by the investigator.

Dates on the record

Started 17 August 2023
Estimated completion 1 June 2025
Registry last updated 12 November 2024
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 12 November 2024.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.